These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6883622)

  • 1. Antitumor activity of didemnin B in the human tumor stem cell assay.
    Jiang TL; Liu RH; Salmon SE
    Cancer Chemother Pharmacol; 1983; 11(1):1-4. PubMed ID: 6883622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.
    Chun HG; Davies B; Hoth D; Suffness M; Plowman J; Flora K; Grieshaber C; Leyland-Jones B
    Invest New Drugs; 1986; 4(3):279-84. PubMed ID: 3546184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay.
    Ludwig R; Alberts DS; Miller TP; Salmon SE
    Cancer Chemother Pharmacol; 1984; 12(3):135-41. PubMed ID: 6705130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and cellular effects of didemnins A and B.
    Crampton SL; Adams EG; Kuentzel SL; Li LH; Badiner G; Bhuyan BK
    Cancer Res; 1984 May; 44(5):1796-801. PubMed ID: 6713383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
    Shin DM; Holoye PY; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber MN; Hong WK
    Invest New Drugs; 1994; 12(3):243-9. PubMed ID: 7896544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.
    Rinehart KL; Gloer JB; Hughes RG; Renis HE; McGovren JP; Swynenberg EB; Stringfellow DA; Kuentzel SL; Li LH
    Science; 1981 May; 212(4497):933-5. PubMed ID: 7233187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of didemnin B, a depsipeptide from the sea.
    Li LH; Timmins LG; Wallace TL; Krueger WC; Prairie MD; Im WB
    Cancer Lett; 1984 Jul; 23(3):279-88. PubMed ID: 6744252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical trial of didemnin B.
    Stewart JA; Low JB; Roberts JD; Blow A
    Cancer; 1991 Dec; 68(12):2550-4. PubMed ID: 1933801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
    Ebrahim el-Zayat AA; Izquierdo MA; Clark GM; Von Hoff DD
    Invest New Drugs; 1995; 13(2):125-131. PubMed ID: 8617574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal and molecular structure of didemnin A, an antiviral depsipeptide.
    Hossain MB; Van Der Helm D; Antel J; Sheldrick GM; Weinheimer AJ; Sanduja SK
    Int J Pept Protein Res; 1996; 47(1-2):20-7. PubMed ID: 8907495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
    Hochster H; Oratz R; Ettinger DS; Borden E
    Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
    Dorr FA; Kuhn JG; Phillips J; von Hoff DD
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays.
    Geldof AA; Mastbergen SC; Henrar RE; Faircloth GT
    Cancer Chemother Pharmacol; 1999; 44(4):312-8. PubMed ID: 10447579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of didemnin B in advanced colorectal cancer.
    Jones DV; Ajani JA; Blackburn R; Daugherty K; Levin B; Patt YZ; Abbruzzese JL
    Invest New Drugs; 1992 Aug; 10(3):211-3. PubMed ID: 1428730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay.
    Jiang TL; Salmon SE; Liu RM
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):263-70. PubMed ID: 6681771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
    Siu LL; Attardo G; Izbicka E; Lawrence R; Cerna C; Gomez L; Davidson K; Finkle C; Marsolais C; Rowinsky EK; Von Hoff DD
    Ann Oncol; 1998 Aug; 9(8):885-91. PubMed ID: 9789612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of RA-700, a cyclic hexapeptide from Rubiae Radix, in the human tumor clonogenic assay.
    Inoue K; Mukaiyama T; Kobayashi T; Ogawa M
    Invest New Drugs; 1986; 4(3):231-6. PubMed ID: 3818226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Survey of Didemnin Depsipeptide Production in
    Stankey RJ; Johnson D; Duggan BM; Mead DA; La Clair JJ
    Mar Drugs; 2023 Jan; 21(2):. PubMed ID: 36827097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells.
    Jiang TL; Liu RH; Salmon SE
    Invest New Drugs; 1983; 1(1):21-5. PubMed ID: 6678854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of protein synthesis inhibition by didemnin B in vitro.
    SirDeshpande BV; Toogood PL
    Biochemistry; 1995 Jul; 34(28):9177-84. PubMed ID: 7619818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.